In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer to buy Sanofi's Campto if Aventis buyout happens

Executive Summary

Contingent upon the successful takeover of Aventis by Sanofi-Synthelabo, Pfizer will acquire worldwide exclusive rights (outside of Japan) to Sanofi's (now Aventis's) colorectal cancer drug Campto (irinotecan) for €510mm ($620mm).
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register